Table 4.
Chemotherapy regimens for cancer of unknown primary site
| Chemotherapy (mg/m2) | Interval (weeks) | Histopathology |
|---|---|---|
| Paclitaxel 175 Day 1 Carboplatin 5 AUC Day 1 |
3 | Adenoca and SCC |
| Docetaxel 75 Day 1 Carboplatin 5 AUC Day 1 |
3 | Adenoca and SCC |
| Cisplatin 60–75 Day 1 Gemcitabine 1000 Days 1 and 8 |
3 | Adenoca and SCC |
| Docetaxel 75 Day 1 Gemcitabine 1000 Days 1 and 8 |
3 | Adenoca |
| Oxaliplatin 85–130 Day 1 Capecitabine 2000 Days 1 and 8 |
3 | Adenoca |
| Gemcitabine 1000 Days 1 and 8 Irinotecan 100 Days 1 and 8 |
3 | Adenoca |
| Oxaliplatin 85 Leucovorin 400 5FU 400 bolus 5FU 2400 48 h continuous infusion |
2 | SCC |
| Docetaxel 75 Day 1 Cisplatin 75 Day 1 5FU 750 Days 1–5 continuous infusion |
3 | SCC |
| Cisplatin 20 Days 1–5 5FU 700 Days 1–5 continuous infusion |
3 | SCC |
| Cisplatin 75 Day 1 Etoposide Day 1–3 |
3 | Poorly differentiated carcinoma Neuroendocrine-feature CUP |
Adenoca adenocarcinoma, SCC squamous-cell carcinoma, CUP cancer of unknown primary site